EGFR and non-small cell lung carcinoma: Activation of the IGF-1 receptor through IGF-2 overexpression has been identified both in clinical specimens and in cell lines of NSCLC EGFR mutated osimertinib resistant and proposed as a mechanism of acquired resistance.